Endogenous tripeptide

Glutathione

Glutathione is an endogenous tripeptide of glutamate, cysteine and glycine; after a 2 g/m2 intravenous infusion in 10 healthy volunteers its plasma half-life was 14.1 ± 9.2 minutes.1,2

Strong evidence (the app's grade, not a conclusion of the sources); the cited sources hold no human subcutaneous dataGet the app

Level after one dose

Glutathione after one dose: 50% at ~15 min, 25% at 30 min, 12.5% at 45 min.

Drawn from the half-life in the app's model, ~15 min. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

3%The 24th most tracked compound in Milligram: of people who track compounds in Milligram logged Glutathione in the last 90 days.

Schedule

  1. Daily20%
  2. Every other day46%
  3. Twice a week23%
  4. Weekly9%
  5. Less often1%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 100 and 200 mg per dose; the median was 150 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Glutathione who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

2

Overview

Glutathione (GSH) is an endogenous tripeptide that consists of glutamate, cysteine and glycine and is one of the main intracellular antioxidants in human cells.1

The app's figures for glutathione are a half-life of about 15 minutes, a time to peak of about 15 minutes, 90% bioavailability by subcutaneous injection and a typical dose of 200 to 600 mg/day. None of the cited sources reports a half-life, time to peak, bioavailability or dose for subcutaneous injection in people. The human half-life among the cited sources is for an intravenous infusion, 14.1 ± 9.2 minutes in 10 healthy volunteers, reported by Aebi and colleagues in 1991.2

Reviewers describe glutathione as central to the maintenance of intracellular redox balance, with roles in detoxification and in several enzymatic reactions.4,1 After an intravenous infusion of 2 g/m2 in 10 healthy volunteers, plasma cysteine rose from 8.9 ± 3.5 to 114 ± 45 µmol/l, while total cyst(e)ine in plasma fell.2

Postulated action on skin pigment

Sonthalia and colleagues write that among the mechanisms postulated for its antimelanogenic properties, inhibition of the tyrosinase enzyme, skewing of melanogenesis from the darker eumelanin to the lighter phaeomelanin, and scavenging of free radicals seem the most important.4 A 2026 narrative review adds that translating these mechanisms into clinically meaningful outcomes remains uncertain.1

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~15 min
Bioavailability
90%
Typical dose
200–600 mg/day
Route
SubQ
Time to peak
~15 min

The half-life row below is the app's figure; the source's figure is for a different route.2

Table 4.1Half-life and pharmacokinetics2 rows
ParameterApp's figureReported in the cited sources
Half-life~15 minutes14.1 ± 9.2 min after a 2 g/m2 intravenous infusion in 10 healthy volunteers, with an elimination rate constant of 0.063 ± 0.027 min-1; none of the cited sources reports a subcutaneous half-life.2
Bioavailability (SubQ)~90%None of the cited sources reports subcutaneous bioavailability; after a single oral dose of 3 g in 7 healthy volunteers, plasma glutathione did not increase significantly.5

Illustration only: the curve below uses the app's half-life and time to peak of about 15 minutes, which none of the cited sources reports for subcutaneous injection.

Level over 3 days

Interval between doses

Level, as a share of the peak after one 200 mg dose

As studied: every day6. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 0.25 hours. It is not a measured level or a suggested dose.

Oral supplementation has given different results across studies. A single 3 g oral dose did not significantly raise plasma glutathione in 7 healthy volunteers (Witschi and colleagues, 1992).5 Daily oral glutathione of 250 or 1,000 mg raised glutathione levels in blood versus baseline over 6 months in 54 non-smoking adults (Richie and colleagues, 2015).8 A 2015 crossover trial in 20 volunteers with metabolic syndrome, sponsored by Laboratoires Le Stum, which supplied the sublingual form and employs two of the authors, reported higher plasma total and reduced glutathione and a higher GSH/GSSG ratio (p=0.003) with that form than with oral glutathione (Schmitt and colleagues).10

In 15 people with Parkinson's disease, one 200 mg intranasal dose raised brain glutathione measured by magnetic resonance spectroscopy: there was no increase at 8 minutes, and levels were significantly higher than baseline at the remaining time points over about an hour (Mischley and colleagues, NPJ Parkinson's Disease, 2016).11 The authors list the single dose, the 1-hour observation period and the lack of a placebo arm as limitations of this proof-of-concept study.11

5

Human studies

Table 5.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Aebi and colleagues, 19912Pharmacokinetic study; no sponsor stated in the short record cited10 healthy volunteers2 g/m2 intravenous infusionHalf-life 14.1 ± 9.2 min; total plasma glutathione 17.5 ± 13.4 to 823 ± 326 µmol/l; urinary glutathione excretion up 300-fold in 90 min.
Richie and colleagues, 20158Randomised, double-blind, placebo-controlled; blood levels reported versus baseline; no sponsor stated in the short record cited54 non-smoking adultsOral 250 or 1,000 mg/day, 6 months, then a 1-month washoutAt 6 months at 1,000 mg/day, erythrocyte, plasma and lymphocyte GSH rose 30-35% and buccal cell GSH 260% (P < 0.05); at 250 mg/day, blood GSH rose 17% and erythrocyte GSH 29% (P < 0.05).
Sinha and colleagues, 20189Pilot study of an oral liposomal preparation, with no placebo group; funded by Researched Nutritionals, LLC, which supplied the product12 healthy adults assessedOral liposomal 500 or 1000 mg/day, 1 monthMaximum increases after 2 weeks of 40% in whole blood, 25% in erythrocytes, 28% in plasma and 100% in PBMCs (P<0.05); no differences between dose groups, but statistical power was limited by the small sample size.
Cascinu and colleagues, 19956Randomised, double-blind, placebo-controlled; no sponsor stated in the short record cited50 patients with advanced gastric cancer on a weekly cisplatin-based regimen1.5 g/m2 intravenously over 15 minutes before cisplatin, then 600 mg intramuscularly on days 2 to 5; assessed at 9 and 15 weeksAfter 15 weeks, neurotoxicity in 4 of 24 assessable patients on glutathione versus 16 of 18 on placebo (P = .0001).
Hauser and colleagues, 200912Randomised, double-blind, placebo-controlled pilot; no sponsor stated in the short record cited21 people with Parkinson's disease, 11 on glutathione and 10 on placebo; one on glutathione withdrew for personal reasons before any efficacy assessment1,400 mg intravenously three times a week for 4 weeksNo significant differences in UPDRS changes; ADL plus motor scores improved by a mean of 2.8 units more on glutathione over 4 weeks (P = 0.32).
Mischley and colleagues, 20177Double-blind, placebo-controlled phase IIb; funded by the Michael J. Fox Foundation45 people with Hoehn and Yahr stage 1-3 Parkinson's diseaseIntranasal placebo, 100 mg or 200 mg three times daily for 3 months, then a 1-month washoutAll groups improved including placebo; neither dose was superior to placebo; one high-dose participant, with a history of anxiety and tachycardia, was newly diagnosed with cardiomyopathy about 5 weeks in, and the authors write that it is unclear whether this is related to the study medication.
Arjinpathana and Asawanonda, 201213Randomised, double-blind, placebo-controlled; no sponsor stated in the short record cited60 otherwise healthy medical studentsOral 500 mg/day in two divided doses, 4 weeksMelanin index fell at all six sites; the reduction beat placebo at two sites (p = 0.021 and 0.036).

Deeper analysis: Aebi and colleagues, intravenous pharmacokinetics (1991)

Aebi, Assereto and Lauterburg gave 10 healthy volunteers an intravenous infusion of 2 g/m2 of glutathione and followed plasma and urine thiols.2 The elimination rate constant of 0.063 ± 0.027 min-1 corresponded to a half-life of 14.1 ± 9.2 minutes.2

Deeper analysis: Richie and colleagues, oral glutathione over 6 months (2015)

Richie and colleagues randomised 54 non-smoking adults to oral glutathione at 250 or 1,000 mg/day or placebo for 6 months and measured glutathione in blood, erythrocytes, plasma, lymphocytes and buccal cells.8 Blood glutathione rose versus baseline after 1, 3 and 6 months at both doses, and in most cases the increases were dose and time dependent.8 The oxidized to reduced glutathione ratio in whole blood fell in both dose groups after 6 months, and natural killer cell cytotoxicity, a secondary outcome measured in a subset of subjects, rose more than twofold in the high-dose group versus placebo at 3 months (P < 0.05).8 Levels returned to baseline after a 1-month washout.8

Deeper analysis: Cascinu and colleagues, cisplatin neurotoxicity (1995)

Cascinu and colleagues randomised 50 patients with advanced gastric cancer on a weekly cisplatin-based regimen to glutathione or normal saline in a double-blind, placebo-controlled trial.6 At week 9, no patients in the glutathione arm showed clinically evident neuropathy against 16 in the placebo arm, and after week 15 four of 24 assessable patients in the glutathione arm had neurotoxicity against 16 of 18 on placebo (P = .0001).6 The response rate was 76% (20% complete response) with glutathione and 52% (12% complete response) with placebo.6 The authors concluded that glutathione "is a promising and effective new drug for the prevention of CDDP-induced neuropathy".6 Only 42 of the 50 patients were assessable after week 15 (24 on glutathione, 18 on placebo), with no reason given for the other 8, and the cited record does not mention adverse events.6

Smyth and colleagues (Annals of Oncology, 1997) randomised 151 women with ovarian cancer to cisplatin with or without glutathione, to test whether glutathione would allow six cycles of cisplatin at 100 mg/m2 without dose reduction for toxicity.14 Six courses of cisplatin at any dose were received by 58% versus 39% (P = 0.04), and among those patients the reduction in creatinine clearance differed between the glutathione and control groups, 74% versus 62% (P = 0.006).14 Quality of life scores improved significantly in the glutathione group in six areas, while the difference in clinically assessed response, 73% versus 62%, was not statistically significant (P = 0.25).14 A 2026 systematic review and network meta-analysis of 25 randomised trials involving 1625 patients by Geum and colleagues, from Hanyang University, reported that no intervention significantly reduced all-grade chemotherapy-induced neuropathy compared with placebo.15 Glutathione was associated with a reduced incidence of grade 3/4 neuropathy (OR 0.34, 95% CrI 0.13-0.79), but these findings were not retained in analyses restricted to double-blind studies, and the authors regard the associations as preliminary.15

Deeper analysis: Hauser and colleagues, intravenous glutathione in Parkinson's disease (2009)

Hauser and colleagues randomised 21 people with Parkinson's disease whose motor symptoms were not adequately controlled on their current medication, 11 to intravenous glutathione 1,400 mg and 10 to placebo, three times a week for 4 weeks; one participant assigned to glutathione withdrew for personal reasons before any efficacy assessment.12 There were no significant differences in changes in UPDRS scores: ADL plus motor scores improved by a mean of 2.8 units more on glutathione over the 4 weeks (P = 0.32) and worsened by a mean of 3.5 units more over the next 8 weeks (P = 0.54).12 The authors wrote that the preliminary efficacy data "suggest the possibility of a mild symptomatic effect, but this remains to be evaluated in a larger study".12

In the phase IIb intranasal trial of Mischley and colleagues (Journal of Parkinson's Disease, 2017), 45 people were randomised to placebo, 100 mg or 200 mg intranasal glutathione three times daily for three months, and all groups improved, including placebo.7 The high-dose group improved in total UPDRS (-4.6 (4.7), P = 0.0025) and in the motor subscore (-2.2 (3.8), P = 0.0485) over baseline, and neither treatment group was superior to placebo.7 One participant in the 600 mg/day cohort, with a history of anxiety and tachycardia, withdrew with tachycardia and cardiomyopathy diagnosed at an annual cardiology appointment about 5 weeks in, and the tachycardia resolved after the study medicine stopped; the authors write that "It is unclear whether the single incident of cardiomyopathy in this study is related to the study medication".7 The participant's cardiologist recommended withdrawal because of literature on reductive stress damaging cardiac cells, and the authors add that research in rodents suggests that reductive stress, attributable to an overabundance of antioxidants, may result in insult to cardiomyocytes.7 The trial was funded by the Michael J. Fox Foundation, and the first author is listed as the founder of NeurRx Social Purpose Corporation.7

A 2012 trial by Arjinpathana and Asawanonda randomised 60 otherwise healthy medical students to oral glutathione 500 mg/day in two divided doses or placebo for 4 weeks and measured melanin indices at six sites.13 Melanin indices decreased at all six sites on glutathione, and the reductions were statistically significantly greater than placebo at two sites (p-values = 0.021 and 0.036).13 The authors concluded that oral glutathione results in a lightening of skin color "in a small number of subjects" and that long-term safety has not been established.13 Both glutathione and placebo were very well tolerated.13

A 2019 systematic review by Dilokthornsakul and colleagues, Naresuan University, included four studies of glutathione on skin color in healthy volunteers, three placebo-controlled RCTs and one single-arm trial, one topical and the others oral at 250 to 500 mg/day.16 It found that oral glutathione at 500 mg/day and topical 2.0% oxidized glutathione could brighten skin color in sun-exposed area by melanin index, with no significant differences in sun-protected area.16 It concluded that current evidence is "still inconclusive due to the quality of included studies and inconsistent findings".16 A 2025 systematic review by Sarkar and colleagues reported that five randomized controlled trials and a single open-arm clinical study of oral glutathione at 250 mg once a day, 250 mg twice a day and 500 mg once a day showed a significant reduction in the melanin index compared to placebo, and called topical and oral glutathione "moderately efficacious".17 It also reported that almost an equal number of studies have low and high risk of bias, and that topical versus oral glutathione have minimal versus substantial adverse effects but are unsustainable, with variable costs.17 For intravenous glutathione it reported only one placebo-controlled study, with 6/16 (37.5%) against 3 (18.7%) (p = 0.054), and concluded that "IV glutathione is contraindicated due to lack of efficacy and side effects".17

Aloraini and colleagues describe the one randomised trial of intravenous glutathione for skin lightening, by Zubair and colleagues in 2016: 1,200 mg with vitamin C twice weekly for 6 weeks, 50 enrolled and 32 completed, judged by clinical assessment and subjective satisfaction.1 In the review's account, 37.5% of the treatment group observed significant improvement compared to baseline whereas this was insignificant in the placebo group; it calls the study constrained by low sample size, short follow-up and non-standard outcome measures, with concurrent vitamin C making the independent effect of glutathione hard to ascertain.1 Sonthalia and colleagues describe the same trial with n=25 in each group and a high dropout rate from the treatment group (9 of 25), call its design dubious and its analysis apparently flawed, and write that it did not favor IV glutathione as an effective or lasting treatment for skin tone lightening.4

In a 12-week placebo-controlled trial of oral glutathione 250 mg/day, reduced or oxidized, in healthy women, funded by Kyowa Hakko Bio, melanin index at all sites tended to be lower than with placebo, but the differences were not statistically significant (P > 0.05), and there were no serious adverse effects (Weschawalit and colleagues, 2017).20 Adverse reactions (pruritus, macular erythema, transient red spots and tiredness) occurred in five treated participants (13.15%), and pruritus, erythema and red spots also occurred in the placebo group, while two participants had transaminase increases that were temporary and returned to normal within a few weeks.20 The authors list as limitations that the subjects were all female, Asian and of a certain age range.20

7

Doses reported in studies

The doses below are those the studies report, by route (further study doses are in the Human studies table); the app's typical dose is 200 to 600 mg/day by subcutaneous injection, and none of the cited sources reports a subcutaneous dose.

Table 7.1Doses reported in studies7 rows
SourceRoute and doseFrequencyLength
App's figureSubcutaneous, 200–600 mg/dayPer day, as the unit statesNot stated
Aebi and colleagues, 19912Intravenous, 2 g/m2Infusion, frequency not stated in the source textNot stated in the source text
Sinha and colleagues, 20189Oral liposomal, 500 or 1000 mg/dayDaily1 month
Schmitt and colleagues, 201510Sublingual 150 mg tablet (the sponsor's product) or oral 150 mg capsule, 450 mg/day eachThree times a day21 days per period
Mischley and colleagues, 201518Intranasal, 300 or 600 mg/dayThree divided daily doses3 months
Mischley and colleagues, 20177Intranasal, 100 or 200 mgThree times daily3 months, then a 1-month washout
Aloraini and colleagues, 20261Intravenous, 500 mg to 1200 mg per session (across the reviewed skin-lightening studies)Weekly or twice weeklyTypically 4 to 12 weeks, across the reviewed studies of all routes

In the intravenous Parkinson's disease pilot, no participant withdrew because of adverse events and reported adverse events were similar in the glutathione and placebo groups.12 In the phase I/IIa intranasal trial, there were no substantial differences between groups in the number of adverse events reported or observed among all safety measures assessed, and one participant withdrew after a "ringing in her head" attributed to the study medication that resolved over 4 to 6 hours.18 In the phase IIb intranasal trial, one participant in the placebo arm withdrew with chronically irritated sinuses and headaches and one in the 300 mg/day cohort withdrew reporting puffiness under the eyes, both described as attributable to the study intervention, and one in the 600 mg/day cohort withdrew with tachycardia and newly diagnosed cardiomyopathy.7

In the oral liposomal pilot, no serious adverse effects were reported in either dose group, and all potential adverse events were minor and none were attributed to either treatment group.9 In the 60-student oral skin trial, both glutathione and placebo were very well tolerated, and a 2019 systematic review reported that some adverse events, described as nonserious, were reported.13,16 The cited summaries of the 1995 and 1997 cisplatin trials do not report adverse events attributed to glutathione.6,14

In the 2016 intravenous skin-lightening trial of Zubair and colleagues, given with vitamin C, Aloraini and colleagues report increased liver enzyme levels in eight patients, described as transient, and one case of anaphylaxis, with causality for the liver events listed as uncertain.1 The review also lists hypersensitivity and possible renal and endocrine effects among safety concerns for intravenous use.1

For injectable glutathione used for skin lightening, the Philippine FDA advisory of 2019 lists toxic effects on the liver, kidneys and nervous system, the possibility of Stevens Johnson syndrome, and theoretical concerns about long term skin cancer risk, and cites no study for them.3

9

Bloodwork and markers

Sources in this part

  1. 10Schmitt et al., 2015

The app lists no markers to monitor for glutathione. The sublingual versus oral crossover trial, sponsored by Laboratoires Le Stum, also monitored liver function markers and ultra-sensitive C-reactive protein, and reported no significant changes in either, with all values within the range of normality.10

The Philippine FDA's Advisory No. 2019-182 of 5 July 2019 states that "the FDA has not approved any injectable products for skin lightening".3 It also states that injectable glutathione "is approved by FDA Philippines as an adjunct treatment in cisplatin chemotherapy" and that "there are no published clinical trials that have evaluated the use of injectable glutathione for skin lightening".3 In Italy, the product information for Tationil, a glutathione injection given intramuscularly or by slow intravenous injection, lists prophylaxis of neuropathy following chemotherapy with cisplatin or analogues.21

That statement sits beside a 2016 randomised trial of intravenous glutathione for skin lightening (Zubair and colleagues), which Aloraini and colleagues describe and Sonthalia and colleagues call a single study with a "dubious study design and apparently flawed analysis of results".1,4

Sonthalia and colleagues write that, to the best of their knowledge, the indications approved by India's Central Drugs Standard Control Organization for intravenous glutathione are alcoholic fatty liver, alcoholic liver fibrosis, alcoholic liver cirrhosis and alcoholic hepatitis.4 The 2026 review of Aloraini and colleagues states that the Philippine Food and Drug Administration and the Saudi Food and Drug Authority have sounded a warning about intravenous glutathione for cosmetic skin lightening.1 The cited sources include no label or assessment for glutathione from the US FDA, the TGA or the EMA.

The text of the WADA 2026 Prohibited List, in effect from 1 January 2026, does not mention glutathione by name.19 Method M2.2 prohibits intravenous infusions and injections of more than a total of 100 mL per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.19

The cited sources report no subcutaneous pharmacokinetics, bioavailability or dose-response in people, so the app's subcutaneous half-life, time to peak, bioavailability and typical dose are not matched by a cited study. The 2015 and 2018 oral trials that reported increases used 250 to 1,000 mg/day over 1 to 6 months, against a single 3 g dose that did not.5,8,9

For skin lightening, the 2019 review calls the evidence inconclusive, the 2025 review reports a significant melanin index reduction with oral glutathione but lack of efficacy for intravenous glutathione, and the Philippine FDA stated in 2019 that no published clinical trials had evaluated injectable glutathione for that use.16,17,3 For chemotherapy-induced neuropathy, the 1995 trial and the 2026 network meta-analysis differ, with the latter reporting that the glutathione finding for grade 3/4 neuropathy was not retained in analyses restricted to double-blind studies.6,15 Several of the cited records are short summaries that state no sponsor, so who funded those studies is not known from them.

What is the half-life of glutathione?

The app's half-life for glutathione is about 15 minutes. After a 2 g/m2 intravenous infusion in 10 healthy volunteers, Aebi and colleagues reported a half-life of 14.1 ± 9.2 minutes (European Journal of Clinical Investigation, 1991).2 None of the cited sources reports a subcutaneous half-life.

Is glutathione banned by WADA?

The text of the WADA 2026 Prohibited List does not mention glutathione by name.19 Method M2.2 prohibits intravenous infusions and injections of more than 100 mL in total per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.19

Is oral glutathione absorbed?

In 7 healthy volunteers, a single 3 g oral dose produced no significant rise in plasma glutathione, cysteine or glutamate over 270 minutes (Witschi and colleagues, 1992).5 In 54 non-smoking adults, 250 or 1,000 mg/day for 6 months raised glutathione in blood versus baseline at both doses, and levels returned to baseline after a 1-month washout (Richie and colleagues, 2015).8

Does glutathione lighten skin?

A 2019 systematic review of oral and topical glutathione concluded that the evidence is "still inconclusive due to the quality of included studies and inconsistent findings", and that "there is a trend that glutathione might brighten skin color at skin-exposed area".16 In a 2012 trial of 60 healthy medical students, oral glutathione 500 mg/day for 4 weeks reduced melanin indices more than placebo at two of six sites (p = 0.021 and 0.036), and the authors wrote that lightening occurred "in a small number of subjects" and that long-term safety has not been established.13 A 2017 trial of oral glutathione 250 mg/day for 12 weeks found melanin index tended to be lower than placebo but not significantly so (P > 0.05).20 A 2025 review reported a significant melanin index reduction with oral glutathione, with almost equal numbers of low and high risk of bias studies, and concluded that "IV glutathione is contraindicated due to lack of efficacy and side effects".17

Is injectable glutathione approved for skin lightening?

The Philippine FDA stated in Advisory No. 2019-182 that it has not approved any injectable products for skin lightening.3 The same advisory states that injectable glutathione is approved there as an adjunct treatment in cisplatin chemotherapy.3

What side effects have been reported with glutathione?

In the phase IIb intranasal trial, one participant with a history of anxiety and tachycardia withdrew with tachycardia and newly diagnosed cardiomyopathy after a cardiologist recommended withdrawal, and the authors write that it is unclear whether this is related to the study medication.7 In the 2016 intravenous skin-lightening trial of Zubair and colleagues, given with vitamin C, a review reports increased liver enzymes in eight patients and one case of anaphylaxis.1 The Philippine FDA advisory lists toxic effects on the liver, kidneys and nervous system and the possibility of Stevens Johnson syndrome for injectable glutathione used for skin lightening, and cites no study for them.3

14

References

  1. Aloraini K, Alangari A, Arif J, Alkhodairy F. Glutathione for skin lightening via intravenous, oral, and topical routes: a critical narrative review of current evidence, safety, and the evidence-practice gap. J Med Life 2026. PMC13580517
  2. Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 1991. PMID 1907548
  3. Food and Drug Administration (Philippines). FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent. 5 July 2019. FDA Philippines advisory
  4. Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept 2018. PMC5808366
  5. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992. PMID 1362956
  6. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995. PMID 7799029
  7. Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. J Parkinsons Dis 2017. PMC5438472
  8. Richie JP, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015. PMID 24791752
  9. Sinha R, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr 2018 Jan;72(1) (published online 30 Aug 2017). PMC6389332
  10. Schmitt B, Vicenzi M, Garrel C, Denis FM. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol 2015. PMC4536296
  11. Mischley LK, et al. Central nervous system uptake of intranasal glutathione in Parkinson's disease. NPJ Parkinsons Dis 2016. PMC5516583
  12. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009. PMID 19230029
  13. Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat 2012. PMID 20524875
  14. Smyth JF, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997. PMID 9261526
  15. Geum MJ, et al. Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis. Basic Clin Pharmacol Toxicol 2026. PMID 42876024
  16. Dilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione on skin color and other related skin conditions: a systematic review. J Cosmet Dermatol 2019. PMID 30895708
  17. Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025. PMID 39444151
  18. Mischley LK, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov Disord 2015. PMC4609266
  19. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In effect from 1 January 2026. WADA 2026 list
  20. Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol 2017. PMC5413479
  21. Teofarma. Tationil (glutathione) 600 mg powder and solvent for solution for injection. Italian summary of product characteristics (riassunto delle caratteristiche del prodotto), text revised June 2010. Tationil product information